EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Nanotechnology in Advancing Chimeric Antigen Receptor T Cell Therapy for Cancer Treatment

Xuejia Kang iD, Nur Mita iD, Lang Zhou, Siqi Wu, Zongliang Yue iD, R Jayachandra Babu iD, Pengyu Chen iD

Pharmaceutics · 20.09.2024 · 16 (9) · 1228

DOI: 10.3390/pharmaceutics16091228 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 20.09.2024. Verfasst von Xuejia Kang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Materials Research and Education Center, Materials Engineering, Department of Mechanical Engineering, Auburn University, Auburn, AL 36849, USA. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 196 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIH MIRA R35GM133795, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T cell therapy has emerged as a groundbreaking treatment for hematological cancers, yet it faces significant hurdles, particularly regarding its efficacy in solid tumors and concerning associated adverse effects. This review provides a comprehensive analysis of the advancements and ongoing challenges in CAR-T therapy. We highlight the transformative potential of nanotechnology in enhancing CAR-T therapy by improving targeting precision, modulating the immune-suppressive tumor microenvironment, and overcoming physical barriers. Nanotechnology facilitates efficient CAR gene delivery into T cells, boosting transfection efficiency and potentially reducing therapy costs. Moreover, nanotechnology offers innovative solutions to mitigate cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Cutting-edge nanotechnology platforms for real-time monitoring of CAR-T cell activity and cytokine release are also discussed. By integrating these advancements, we aim to provide valuable insights and pave the way for the next generation of CAR-T cell therapies to overcome current limitations and enhance therapeutic outcomes.

Schlagwörter

Stichwörter der Autor:innen

CAR-T therapybarrierscentral nervous system (CNS) tumorsnanotechnology

Autor:innen und Institutionen

  • Materials Research and Education Center, Materials Engineering, Department of Mechanical Engineering, Auburn University, Auburn, AL 36849, USA.
  • Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA.
  • Faculty of Pharmacy, Mulawarman University, Samarinda 75119, Kalimantan Timur, Indonesia.

ORCID-Profile: Xuejia Kang, Nur Mita, Zongliang Yue, R Jayachandra Babu, Pengyu Chen

Förderung

  • NIGMS NIH HHS
  • NIH MIRA R35GM133795
  • NIH HHS
  • Auburn University
  • NIH

Zitieren

APA

Kang, X., Mita, N., Zhou, L., Wu, S., Yue, Z., Babu, R. J., & Chen, P. (2024). Nanotechnology in Advancing Chimeric Antigen Receptor T Cell Therapy for Cancer Treatment. Pharmaceutics, 16(9), 1228. https://doi.org/10.3390/pharmaceutics16091228

Vancouver

Kang X, Mita N, Zhou L, Wu S, Yue Z, Babu RJ, et al. Nanotechnology in Advancing Chimeric Antigen Receptor T Cell Therapy for Cancer Treatment. Pharmaceutics. 2024;16(9):1228. doi:10.3390/pharmaceutics16091228

BibTeX
@article{Kang2024,
  author = {Kang, Xuejia and Mita, Nur and Zhou, Lang and Wu, Siqi and Yue, Zongliang and Babu, R Jayachandra and Chen, Pengyu},
  title = {Nanotechnology in Advancing Chimeric Antigen Receptor T Cell Therapy for Cancer Treatment},
  journal = {Pharmaceutics},
  year = {2024},
  volume = {16},
  number = {9},
  pages = {1228},
  doi = {10.3390/pharmaceutics16091228}
}
Kostenlos starten →